
The European authorization covers treatment of adults with short bowel syndrome, while Zealand continues a U.S. trial and seeks a commercialization partner.
Zealand Pharma said the European Commission has authorized Zeydovio for adults with short bowel syndrome. The marketing authorization applies across EU member states, Iceland, Liechtenstein and Norway.
The company said its next steps include seeking a partner for future commercialization and continuing the Phase 3 EASE-5 trial, which is intended to support a U.S. regulatory submission. Patient recruitment is progressing, according to Zealand.
Zealand said the EU decision was based on the Phase 3 EASE-1 trial, in which twice-weekly treatment reduced parenteral support needs more than placebo. The company said results from long-term extension trials are expected at scientific meetings in 2027.
As of 15:21 UTC Friday, Zealand shares traded at 242.3 Danish kroner, up 0.5% since the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.